Longitudinal assessment of quality of life in early Parkinson’s disease: 5-year follow up study
Objective: To determine changes in HR-QoL in early PD patients during a 5-year follow up period. Background: There is limited evidence on longitudinal changes in…Lentiform fork sign and Wilson Disease
Objective: First description of lentiform fork sign in patients with the diagnosis of Wilson disease. Background: Lentiform fork sign is a rare neuroradiological sign characterized…Effects of Once-Daily Opicapone 50 mg on COMT activity: A Pooled Post-hoc Analysis of Two Phase 1 Studies
Objective: To assess the effects of opicapone (OPC) 50 mg adjunct to carbidopa/levodopa (CD/LD) on catechol-O-methyltransferase (COMT) activity by participants’ baseline characteristics using pooled data…Impact of COVID-19 in Parkinson disease: preliminary analysis from a survey performed in a Peruvian PD cohort.
Objective: To analyze the impact of COVID-19 in Parkinson cases and healthy controls from a Peruvian population. Background: The COVID-19 pandemic have a profound impact…Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease
Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…Prevalence of sleep disorders symptoms in essential tremor
Objective: The aim is to study the prevalence of sleep disorders symptoms in patients with essential tremor (ET). Background: ET is the most common movement…NUS1 Mutation Causing Ataxia, Myoclonus, and Progressive Encephalopathy
Objective: Describe a rare cause of progressive myoclonus, ataxia, developmental delay Background: 37-year-old man with normal birth but delays in developmental milestones presented for evaluation…Level of glial neurotrophic factor in the blood plasma depending on the duration of Parkinson’s disease
Objective: To study the level of glial neurotrophic factor in the blood plasma depending on the duration of PD. Background: Study of the biochemical aspects…IncobotulinumtoxinA for treating chronic sialorrhea due to Parkinson’s disease and other neurological conditions
Objective: To summarize clinical experience with incobotulinumtoxinA (INCO) for treating chronic sialorrhea due to Parkinson’s disease (PD), atypical parkinsonism, stroke, or traumatic brain injury in…CLINICAL CHARACTERSITICS OF ESSENTIAL TREMOR PATIENTS THAT DEVELOPE PARKINSON´S DISEASE: A COHORT BASED STUDY.
Objective: To elucidate the clinical characteristics of those patients previously diagnosed with essential tremor ( ET ) that finally developed a Parkinson´s disease during the follow…
- « Previous Page
- 1
- …
- 131
- 132
- 133
- 134
- 135
- …
- 153
- Next Page »